Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms

Anticancer Research

Volumn 19, Issue 6 B, 1999, Pages 5079-5085

  Parrett, Michelle L ^a   Abou Issa, Hussein M ^a   Alshafie, Galal ^a   Ross, Mary S ^a   Harris, Randall E ^a   Robertson, Fredika M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

4 HPR; Chemoprevention; COX; Cyclooxygenase; Ibuprofen; Rat mammary adenocarcinomas

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIMETHYLBENZ[A]ANTHRACENE; FENRETINIDE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOGENESIS; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; INFLAMMATORY CELL; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RAT; TUMOR CELL;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADENOCARCINOMA; ANIMALS; FEMALE; FENRETINIDE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IBUPROFEN; ISOENZYMES; MAMMARY NEOPLASMS, EXPERIMENTAL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0033380750     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF and Zebro T: Prostaglandins and breast cancer. Lancet 2: 624-626, 1977.
2. Bennett A, Berstock DA, Carroll MA, Stamford IF and Wilson AJ: Breast cancer, its recurrence, and patient survival in relation to tumor prostaglandins. Adv Prostaglandin, Thromboxane, & Leukotriene Res 12: 299-302, 1983.
3. Bennett A, Berstock DA, Raja B and Stamford IF Swival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers. Br J PharmacoL 66: 451P, 1979.
4. Rolland PH, Martin PM, Jacquemeier J, Rolland AM and Toga M: Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64: 1061-1070, 1980.
5. Herschman HR: Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. CancerMetastasis Rev 13: 241-256, 1994.
6. Smith WL, Garavito RM and DeWitt DL: Prostaglandin endoperoxide H synthases (cylooxygenases)-1 and -2. J Biol Chem 271: 33157-33160, 1996.
7. Williams CS and DuBois RN: Prostaglandin endoperoxide synthase: Why two isoforms? Am J Physiol 270: G393-G400, 1996.
8. O'Neill GP and Ford-Hutchinson AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Letts 330: 156-160, 1993.
9. Allison MC, Howatson AG, Torrance CJ, Lee FD and Russell RI: Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 327: 749-754, 1992.
10. Wallace JL: Prostaglandins, NSAIDs, and cytoprotection. Gastroenterol Clin North Am 21: L631-L641, 1992.
11. Eberhart CE and Dubois RN: Eicosanoids and the gastrointestinal tract. Gastroenterology 109: 285-301, 1995.
12. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and Dubois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998.
13. Wu KK: Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles. [Review] J Lab Clin Med 128: 242-245, 1996.
14. Tsujii M and Dubois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 83: 493-501, 1995.
15. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP and Robertson FM: Cyclooxygenase-2 Gene Expression in Human Breast Cancer. Intl J Oncol 10: 503-507, 1997.
16. Koki AT, Edwards DA, Dannenberg AJ, Ornberg RL, Zweifel BS, Meyer DM, Altorki N and Masferrer JL: Cyclooxygenase-2 is expressed in animal and human cancers. Proc Am Assoc Cancer Res 39: 150, 1998.
17. Hwang D, Scollard D, Byrne J and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Institute 90: 455-60, 1998.
18. Liu X-H and Rose DP: Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 56: 5125-5127, 1996.
19. Subbaramaiah K, Terlang N, Ramonetti.JT, Araki R, DeVito B, Weksler BB and Dannenberg AJ: Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 56: 4424-4429, 1996.
20. DuBois RN, Giardiello FM and Smalley WE: Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. [Review] Gastroenterology Clinics of North America 25: 773-91, 1996.
21. Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, McCormick DK, Pereira MA, Crowell JA, Bagheri D, Sigman CC, Boone CW and Kelloff G J: Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCA chemoprevention Drug Development Program. J Cell Biol Suppl. 20: 32-53, 1994.
22. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele VE and Reddy BS: Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent Cancer Res 55: 1464-1472, 1995.
23. Pereira MA, Barnes LH, Steele VE, Kelloff GV and Lubet RA: Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis 17: 373-376, 1996.
24. Narisawa T, Satoh M7 Sano M and Takahashi T: Inhibition of initiation and promotion of N-methylnitrosourea-induced colon carcinogenesis in rats by nonsteroidal anti-inflammatory agent indomethacin. Carcinogenesis 4: 1225-7, 1983.
25. Joarder FS, Abou-Issa H, Robertson FM, Parrett ML, Alshafie G and Harris RE: Growth arrest of DMBA-Induced mammary carcinogenesis with ibuprofen treatment in female Sprague Dawley rats. Oncology Reports 4: 1271-1273, 1997.
26. Robertson FM, Parrett ML, Joarder FS, Ross MS, Abou-Issa H, Alshafie G and Harris RE: Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary Carcinomas. Cancer Letts 122: 165-175, 1998.
27. Harris RE, Namboodiri KK, Stellman SD and Wynder EL: Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Preven Med 24: 119-120, 1995.
28. Harris RE, Namboodiri KK and Farraf WB: Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 7: 203-205, 1996.
29. Harris RE, Namboodiri, KK and Farrar, WB: Epidemiological study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncology Reports 2: 591-592, 1995.
30. Lee PP and Ip, MM: Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostaglan Leukotrien Essen Fat Acid 45: 21-31, 1992.
31. Cohen LA and Karmali RA: Endogenous prostaglandin production by established cultures of neoplastic rat mammary epithelial cells. In Vitro 20: 119-126, 1984.
32. Formelli F, Barua AB and Olsen JA: Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl-b-glucuronide. FASEB J 10: 1014-1024, 1996.
33. Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Grignani F, Formelli F, Menard S, Costa A, Veronesi U and Peierotti MA: N-(4-hydroxyphenyl)-retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoicacid. Cancer Res 53: 6036-6041, 1993.
34. Sheikh MS, Shao Z-M, Li XS, Ordonez JV, Conley BA, Wu S, Dawson MI, Han Q- X, Chao W, Quick T, Niles RM and Fontana JA: (N-(4-hydroxyphenyl)retinamide (4HPR)-mediated biological actions involve retinoid receptor-independent pathways in human-breastcarcinoma. Carcinogenesis 16: 2477-2486, 1995.
35. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
36. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL and Prescott, SM: Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci 93: 4816-4820, 1996.
37. Ristimaki A, Honkanen N, Jankala H, Sipponen P and Harkonen M: Expression of cyclooxygenase -2 in human gastric carcinoma. Cancer Res 57: 1276-1280, 1997.
38. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T and Takahashi T: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-4, 1998.
39. Zimmerman KC, Sarbia M, Weber A-A, Borchard F, Gabbert HE and Schror K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59: 198-204, 1999.
40. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG Moon RC and Pezzuto JM Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-20, 1997.
41. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY and Isakson PC: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40: 1347-65, 1997.